Transgene SA (EPA:TNG)
France · Delayed Price · Currency is EUR 0.9060
-0.0120 (-1.31%)
At close: Jan 30, 2026
Transgene Market Cap
Transgene has a market cap or net worth of €248.09 million as of January 30, 2026. Its market cap has increased by 173.99% in one year.
Market Cap
248.09M
Enterprise Value
262.38M
Revenue
7.58M
Ranking
n/a
PE Ratio
n/a
Stock Price
€0.91
Market Cap Chart
Since March 30, 1998, Transgene's market cap has increased from 151.86M to 248.09M, an increase of 63.37%. That is a compound annual growth rate of 1.78%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 30, 2026 | 248.09M | -5.63% |
| Dec 31, 2025 | 262.87M | 192.89% |
| Dec 31, 2024 | 89.75M | -34.86% |
| Dec 29, 2023 | 137.78M | -16.38% |
| Dec 30, 2022 | 164.76M | -33.52% |
| Dec 31, 2021 | 247.84M | 79.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Nanobiotix | 844.85M |
| MedinCell | 746.80M |
| Valneva SE | 674.24M |
| Genfit | 278.85M |
| Cellectis | 235.06M |
| Innate Pharma | 145.05M |
| ABIONYX Pharma | 134.06M |
| Adocia | 125.40M |